Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

This study is testing whether starting elranatamab — a bispecific antibody treatment for multiple myeloma — shortly after receiving a CAR-T cell therapy called cilta-cel can prevent relapse in patients whose myeloma has high-risk features that make it likely to return. **You may be eligible if...** - You have relapsed/refractory multiple myeloma and recently received cilta-cel CAR-T therapy (within 3–6 months) - You have high-risk genetic features in your myeloma (such as deletion of chromosome 17p, or certain chromosomal rearrangements), or a history of disease outside the bone marrow - You have not shown signs of disease progression after receiving CAR-T therapy - You have previously received more than 2 prior lines of treatment including an immunomodulator, a proteasome inhibitor, and an anti-CD38 antibody **You may NOT be eligible if...** - Your myeloma is progressing after CAR-T therapy - You have not received all the required prior treatment types - You have organ function that would make this treatment unsafe Talk to your doctor to see if this trial is right for you.